Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 2/20 | 0.67 |
| ▸ | LTA4H | P09960 | 1/20 | 0.57 |
| ▸ | GSR | P00390 | 1/20 | 0.56 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 2/20 | 0.52 |
| ▸ | CPB2 | Q96IY4 | 5/20 | 0.48 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7667351 | 0.98 | GABRR1 (0.64) | GABRR1LTA4HGSRRNPEPBLM | |
| SCHEMBL17974330 | 0.98 | GABRR1 (0.70) | GABRR1LTA4HGSRRNPEPBLM | |
| SCHEMBL39271 | 0.98 | GABRR1 (0.70) | GABRR1LTA4HGSRRNPEPBLM | |
| SCHEMBL12173395 | 0.98 | GABRR1 (0.70) | GABRR1LTA4HGSRRNPEPBLM | |
| SCHEMBL1872640 | 0.95 | GABRR1 (0.67) | GABRR1LTA4HGSRRNPEPBLM | |
| SCHEMBL10869353 | 0.95 | GABRR1 (0.67) | GABRR1LTA4HGSRRNPEPBLM | |
| SCHEMBL1882487 | 0.95 | GABRR1 (0.67) | GABRR1LTA4HGSRRNPEPBLM | |
| SCHEMBL3680852 | 0.95 | GABRR1 (0.67) | GABRR1LTA4HGSRRNPEPBLM | |
| SCHEMBL4017002 | 0.95 | GABRR1 (0.67) | GABRR1LTA4HGSRRNPEPBLM | |
| SCHEMBL4020912 | 0.95 | GABRR1 (0.67) | GABRR1LTA4HGSRRNPEPBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12365698-B2 | Application of boron dipyrromethene derivatives in anti-tumor and anti-bacterial therapy | BIOLITEC UNTERNEHMENSBETEILIGUNGS III AG (AT) | 2025-07-22 | — | — | US | disclosed |
| US-11712480-B2 | Heteroaryl sulfone-based conjugation handles, methods for their preparation, and their use in synthesizing antibody drug conjugates | PFIZER INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-20220403377-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS, INC. | 2022-12-22 | — | — | US | disclosed |
| US-20220380388-A1 | Application of Boron Dipyrromethene Derivatives in Anti-Tumor and Anti-Bacterial Therapy | BIOLITEC UNTERNEHMENSBETEILIGUNGS III AG (AT) | 2022-12-01 | — | — | US | disclosed |
| EP-4055022-A1 | APPLICATION OF BORON DIPYRROMETHENE DERIVATIVES IN ANTI-TUMOR AND ANTI-BACTERIAL THERAPY | biolitec Unternehmensbeteiligungs II AG (AT) | 2022-09-14 | — | — | EP | disclosed |
| US-11312957-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20210308276-A1 | HETEROARYL SULFONE-BASED CONJUGATION HANDLES, METHODS FOR THEIR PREPARATION, AND THEIR USE IN SYNTHESIZING ANTIBODY DRUG CONJUGATES | PFIZER INC. (US) | 2021-10-07 | — | — | US | disclosed |
| US-10676740-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-20190345498-A1 | MODIFIED iRNA AGENTS | BANK OF AMERICA, N.A. | 2019-11-14 | — | — | US | disclosed |
| EP-3493853-A1 | HETEROARYL SULFONE-BASED CONJUGATION HANDLES, METHODS FOR THEIR PREPARATION, AND THEIR USE IN SYNTHESIZING ANTIBODY DRUG CONJUGATES | Pfizer Inc (US) | 2019-06-12 | — | — | EP | disclosed |
| EP-0799050-A1 | RADIOLABELED ANNEXIN-GALACTOSE CLUSTER CONJUGATES | NEORX CORPORATION (US) | 1997-10-08 | — | — | EP | disclosed |
| EP-0794788-A1 | HEPATIC-DIRECTED COMPOUNDS AND REAGENTS FOR PREPARATION THEREOF | NEORX CORPORATION (US) | 1997-09-17 | — | — | EP | disclosed |
| WO-1997000675-A1 | MONO- AND DISULFO-SUBSTITUTED ANTHRAQUINONES AND THEIR USE FOR THE TREATMENT OF BONE MATRIX DISORDERS | BOONVILLE LIMITED (VG) | 1997-01-09 | — | — | WO | disclosed |
| WO-1996017613-A1 | HEPATIC-DIRECTED COMPOUNDS AND REAGENTS FOR PREPARATION THEREOF | NEORX CORPORATION (US) | 1996-06-13 | — | — | WO | disclosed |
| WO-1996017618-A1 | RADIOLABELED ANNEXIN-GALACTOSE CLUSTER CONJUGATES | NEORX CORPORATION (US) | 1996-06-13 | — | — | WO | disclosed |
| US-5324648-A | Anticoagulants; antitumor agents | GEORGIA TECH RESEARCH CORPORATION (US) | 1994-06-28 | — | — | US | disclosed |
| WO-1993020094-A1 | HAPTENS, TRACERS, IMMUNOGENS AND ANTIBODIES FOR QUINOLINE | ABBOTT LABORATORIES (US) | 1993-10-14 | — | — | WO | disclosed |
| US-5089633-A | Protease inhibitors, antiinflammatory agents | GEORGIA TECH RESEARCH CORPORATION (US) | 1992-02-18 | — | — | US | disclosed |
| EP-0074787-B1 | RENALLY ACTIVE DIPEPTIDES | SMITHKLINE BECKMAN CORPORATION (US) | 1985-03-27 | — | — | EP | disclosed |
| EP-0074787-A1 | Renally active dipeptides | SMITHKLINE BECKMAN CORPORATION (US) | 1983-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12365698-B2 | Application of boron dipyrromethene derivatives in anti-tumor and anti-bacterial therapy | BTD, TLR5, TLR8 | GABRR1 4674/4885LTA4H 3535/4885GSR 3234/4885 |
| US-20220403377-A1 | MODIFIED iRNA AGENTS | NCL, HNRNPA0, HNRNPA1 | GABRR1 3445/4885LTA4H 4028/4885GSR 1074/4885 |
| US-20220380388-A1 | Application of Boron Dipyrromethene Derivatives in Anti-Tumor and Anti-Bacterial Therapy | BTD, TLR5, TLR8 | GABRR1 4674/4885LTA4H 3535/4885GSR 3234/4885 |
| US-20190345498-A1 | MODIFIED iRNA AGENTS | NCL, HNRNPA0, HNRNPA1 | GABRR1 3445/4885LTA4H 4028/4885GSR 1074/4885 |
| US-10676740-B2 | Modified iRNA agents | NCL, HNRNPA0, HNRNPA1 | GABRR1 3445/4885LTA4H 4028/4885GSR 1074/4885 |
| US-11312957-B2 | Modified iRNA agents | NCL, HNRNPA0, HNRNPA1 | GABRR1 3445/4885LTA4H 4028/4885GSR 1074/4885 |
| US-11712480-B2 | Heteroaryl sulfone-based conjugation handles, methods for their preparation, and their use in synthesizing antibody drug conjugates | SULT1E1, SULT2A1, STS | GABRR1 444/4885LTA4H 1101/4885GSR 927/4885 |
| US-20210308276-A1 | HETEROARYL SULFONE-BASED CONJUGATION HANDLES, METHODS FOR THEIR PREPARATION, AND THEIR USE IN SYNTHESIZING ANTIBODY DRUG CONJUGATES | SULT1E1, FCGRT, SULT2A1 | GABRR1 265/4885LTA4H 1361/4885GSR 1419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.